Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep 11;22(18):9839.
doi: 10.3390/ijms22189839.

Nuclear and Mitochondrial Genome, Epigenome and Gut Microbiome: Emerging Molecular Biomarkers for Parkinson's Disease

Affiliations
Review

Nuclear and Mitochondrial Genome, Epigenome and Gut Microbiome: Emerging Molecular Biomarkers for Parkinson's Disease

Gleyce Fonseca Cabral et al. Int J Mol Sci. .

Abstract

Background: Parkinson's disease (PD) is currently the second most common neurodegenerative disorder, burdening about 10 million elderly individuals worldwide. The multifactorial nature of PD poses a difficult obstacle for understanding the mechanisms involved in its onset and progression. Currently, diagnosis depends on the appearance of clinical signs, some of which are shared among various neurologic disorders, hindering early diagnosis. There are no effective tools to prevent PD onset, detect the disease in early stages or accurately report the risk of disease progression. Hence, there is an increasing demand for biomarkers that may identify disease onset and progression, as treatment-based medicine may not be the best approach for PD. Over the last few decades, the search for molecular markers to predict susceptibility, aid in accurate diagnosis and evaluate the progress of PD have intensified, but strategies aimed to improve individualized patient care have not yet been established.

Conclusions: Genomic variation, regulation by epigenomic mechanisms, as well as the influence of the host gut microbiome seem to have a crucial role in the onset and progress of PD, thus are considered potential biomarkers. As such, the human nuclear and mitochondrial genome, epigenome, and the host gut microbiome might be the key elements to the rise of personalized medicine for PD patients.

Keywords: Parkinson’s disease; biomarkers; epigenetics; genetics; microbiome; mitochondria; neurodegeneration; non-coding RNAs; precision medicine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
Molecular factors that may be involved in Parkinson’s Disease onset and progression. There are various points of view in PD biomarker research, thus, there is a lot to be understood from the earliest molecular alterations until de development of the firsts symptoms. In this review, we decided to discuss these multi-omics factors to highlight how they can be applied for preventive measures.
Figure 2
Figure 2
Mechanisms of gene expression regulation. Gene expression is regulated by a network which includes chromatin modulators, with the addition of molecules such as acetyl and/or methyl in histones and the methylation of DNA strands. Additionally, ncRNAs participated in several steps both in transcriptional and post-transcriptional levels. Within the nucleus, ncRNAs may play the role of enhancers, transcription factors or as gene silencing tools. In cytoplasm, they may inhibit RNA translation or modulate the action of other ncRNAs and be used as a sponge of RBP, inducing mRNA degradation.

References

    1. GBD 2016 Neurology Collaborators Global, regional, and national burden of neurological disorders, 1990-2016: A systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2019;18:459–480. doi: 10.1016/S1474-4422(18)30499-X. - DOI - PMC - PubMed
    1. Vinasco-Sandoval T., Moreira F.C., Vidal A.F., Pinto P., Ribeiro-dos-Santos A.M., Cruz R.L.S., Cabral G.F., Anaissi A.K.M., Lopes K.d.P., Ribeiro-dos-Santos A. Global analyses of expressed piwi-interacting RNAs in gastric cancer. Int. J. Mol. Sci. 2020;21:7656. doi: 10.3390/ijms21207656. - DOI - PMC - PubMed
    1. Vidal A.F., Ribeiro-dos-Santos A.M., Vinasco-Sandoval T., Magalhães L., Pinto P., Anaissi A.K.M., Demachki S., de Assumpção P.P., dos Santos S.E.B., Ribeiro-dos-Santos A. The comprehensive expression analysis of circular RNAs in gastric cancer and its association with field cancerization. Sci. Rep. 2017;7:14551. doi: 10.1038/s41598-017-15061-w. - DOI - PMC - PubMed
    1. Reed X., Bandrés-Ciga S., Blauwendraat C., Cookson M.R. The role of monogenic genes in idiopathic Parkinson’s disease. Neurobiol. Dis. 2019;124:230–239. doi: 10.1016/j.nbd.2018.11.012. - DOI - PMC - PubMed
    1. Cook Shukla L., Schulze J., Farlow J., Pankratz N.D., Wojcieszek J., Foroud T. Parkinson Disease Overview. GeneReviews® 2004. [(accessed on 25 July 2019)]. Available online: https://www.ncbi.nlm.nih.gov/books/NBK1223/